晚期糖基化终产物受体：慢性阻塞性肺疾病的新治疗靶点？
Receptor for advanced glycation end products: a new theraputic target for chronic obstructive pulmonary disease?
机构信息
Division of Pulmonar Diseases, State Key Laboratory of Biotherapy of China, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
出版信息
Arch Med Res. 2013 Jan;44(1):75-6. doi: 10.1016/j.arcmed.2012.12.003. Epub 2013 Jan 1.
Receptor for advanced glycation end products (RAGE), a multiligand receptor, has been suggested to be implicated in inflammatory response. However, its role in chronic obstructive pulmonary disease (COPD) has not been well elucidated. Recently, several studies reported RAGE and its common ligands were upregulated in airways and lung tissues from COPD smokers. Moreover, inhibition of RAGE activation significantly attenuated cigarette smoke extract or bacteria-induced pulmonary inflammation. Based on these findings, a conclusion could be made that ligand-activated RAGE may play a key role in COPD and thus RAGE could be a new therapeutic target for COPD.
晚期糖基化终产物受体（RAGE）是一种多配体受体，被认为与炎症反应有关。然而，其在慢性阻塞性肺疾病（COPD）中的作用尚未得到充分阐明。最近的几项研究表明，RAGE 及其常见配体在 COPD 吸烟者的气道和肺组织中上调。此外，抑制 RAGE 激活可显著减轻香烟烟雾提取物或细菌引起的肺部炎症。基于这些发现，可以得出结论，配体激活的 RAGE 可能在 COPD 中起关键作用，因此 RAGE 可能成为 COPD 的一个新的治疗靶点。
Zotero 插件